Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients.

Integrative cancer science and therapeutics Pub Date : 2018-12-01 Epub Date: 2018-11-29 DOI:10.15761/ICST.1000293
Amanda Graul-Conroy, Margo Hoover-Regan, Kenneth B DeSantes, Paul M Sondel, Natalie S Callander, Walter L Longo, William E Fahl
{"title":"Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients.","authors":"Amanda Graul-Conroy,&nbsp;Margo Hoover-Regan,&nbsp;Kenneth B DeSantes,&nbsp;Paul M Sondel,&nbsp;Natalie S Callander,&nbsp;Walter L Longo,&nbsp;William E Fahl","doi":"10.15761/ICST.1000293","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models.</p><p><strong>Methods: </strong><i>A</i>drenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11-1 formulation) was orotopically applied to three patients (ages 24-29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide.</p><p><strong>Results: </strong>OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both \"Grade 3 OM\" duration and \"any OM\" duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients.</p><p><strong>Conclusion: </strong>Orotopically applied NG11-1 vasoconstrictor formulation substantially reduced the incidence and severity of \"Grade 3\" and \"any\" oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects.</p>","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907163/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative cancer science and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/ICST.1000293","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/11/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models.

Methods: Adrenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11-1 formulation) was orotopically applied to three patients (ages 24-29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide.

Results: OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both "Grade 3 OM" duration and "any OM" duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients.

Conclusion: Orotopically applied NG11-1 vasoconstrictor formulation substantially reduced the incidence and severity of "Grade 3" and "any" oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects.

Abstract Image

Abstract Image

Abstract Image

局部血管收缩剂降低口腔黏膜炎严重程度:3例骨髓移植患者的病例报告。
背景:在>90%接受环磷酰胺+全身照射(CY+TBI)治疗方案的骨髓移植患者中,历史上观察到3级口腔黏膜炎(OM)。先前的研究表明,在两个临床前动物模型中,口腔局部应用肾上腺素能血管收缩剂可预防高达100%的放射性口腔黏膜炎。方法:将肾上腺素能血管收缩剂(即NG11-1水酒精制剂中的苯肾上腺素)应用于3例接受CY+TBI调理方案的患者(24-29岁);他们与未接受口腔局部血管收缩剂治疗的5名对照组进行了比较。在威斯康星大学成人骨髓移植项目中,所有患者接受急性淋巴细胞白血病CY+TBI调理方案。在为期7天的Cy+TBI调理方案中,每次放疗或化疗前20分钟,血管收缩剂局部应用于口腔,然后患者接受1.5 Gy全身放疗或静脉注射环磷酰胺。结果:在三周的时间内,使用以下方法对OM严重程度进行评分:i)身体评估,ii)口腔每日照片,iii)口腔疼痛和口腔功能评分表,iv)记录麻醉品消耗。血管收缩剂治疗患者的“3级OM”持续时间和“任何OM”持续时间均明显低于5名对照患者。虽然5例对照患者中有3例使用了鼻胃管或全肠外营养,但在3例血管收缩剂治疗的患者中没有使用这些支持护理措施。结论:与接受相同CY+TBI治疗方案的对照患者相比,口腔局部应用NG11-1血管收缩剂制剂可显著降低“3级”和“任何”口腔黏膜炎的发生率和严重程度。液体口腔外用制剂使用方便,无副作用,患者容易耐受。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信